Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Director · Chief Executive Officer | May 05, 2025 | May 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date May 05, 2025 · Filed May 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 282,731.157 |
Reported balance
After 2025-05-05 transaction · row 1
1 source rowRow 1 · 2025-05-05 · Purchase · Acquired 34,000 · Balance 282,731.157 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.765 to $8.850, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.765 to $8.850, inclusive. The reporting person undertakes to provide to Organon & Co. ("Organon"), any security holder of Organon, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2022 Filed May 6, 2022 00:45 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,270 | $32.08 | $40,741.60 |
DisclosureSEC source: 0001104659-22-056625 · tm2214603-1_4seq1.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,009 Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:45 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 2,631 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056625 · tm2214603-1_4seq1.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 2,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055425 · tm2214297-1_4seq1.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,709 Underlying: Common Stock · 2,709 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,523 | $32.33 | $49,238.59 |
DisclosureSEC source: 0001104659-22-055425 · tm2214297-1_4seq1.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,648 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:38 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 2,709 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055425 · tm2214297-1_4seq1.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:02 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 198,412 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042353 · tm2211465-1_4seq1.xml · derivative · entry 2 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,412 Underlying: Common Stock · 198,412 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:02 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 64,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042353 · tm2211465-1_4seq1.xml · derivative · entry 1 Ali Kevin · CIK 0001859698 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,414 Underlying: Common Stock · 64,414 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 14,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029456 · tm228175-4_4seq1.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,529 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 6,469 | $37.57 | $243,040.33 |
DisclosureSEC source: 0001104659-22-029456 · tm228175-4_4seq1.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,462 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 14,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029456 · tm228175-4_4seq1.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 20:59 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 133,928 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033654 · doc4.xml · derivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,928 Underlying: Common Stock · 133,928 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 515,471 | $0.00 Strike: $36.11 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 15 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,471 Underlying: Common Stock · 515,471 shares Expires 2031-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 63,578 | $0.00 Strike: $36.91 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 14 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,578 Underlying: Common Stock · 63,578 shares Expires 2030-04-30 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F11 · derivative.exercise_date: 21,191 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 59,412 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 13 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,412 Underlying: Common Stock · 59,412 shares Expires 2029-05-02 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F10 · derivative.exercise_date: 39,608 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 77,028 | $0.00 Strike: $27.44 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 12 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,028 Underlying: Common Stock · 77,028 shares Expires 2028-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 72,063 | $0.00 Strike: $30.40 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 11 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,063 Underlying: Common Stock · 72,063 shares Expires 2027-05-04 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 38,120 | $0.00 Strike: $25.98 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 10 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,120 Underlying: Common Stock · 38,120 shares Expires 2026-05-09 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 60,821 | $0.00 Strike: $28.44 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 9 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,821 Underlying: Common Stock · 60,821 shares Expires 2025-04-30 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 27,021 | $0.00 Strike: $27.67 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 8 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,021 Underlying: Common Stock · 27,021 shares Expires 2024-05-01 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 88,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 7 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,121 Underlying: Common Stock · 88,121 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 11,393 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 6 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,393 Underlying: Common Stock · 11,393 shares Expires 2022-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 14,528 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 5 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,528 Underlying: Common Stock · 14,528 shares Expires 2021-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 66,477 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,477 Underlying: Common Stock · 66,477 shares Expires 2024-05-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 5,420 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,420 Underlying: Common Stock · 5,420 shares Expires 2023-05-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:24 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 2,631 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,631 Underlying: Common Stock · 2,631 shares Expires 2022-05-03 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.